Endothelial cell function can ameliorate under safer drugs, such as Melatonin-Adenosine.
Sergio Stagnaro, Private. Specialist in Blood, Gastrointestinal, and Metabolic Diseases.
10 October 2004
Sirs,
the authors conclude their intriguing paper stating that “The increase of resting [Ca2+]i after incubation with cerivastatin or fluvastatin may provide an explanation for the direct effects of statins on the endothelial-dependent vasodilatation and restoration of endothelial activity in vivo”. In addition, it is remembered that inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase (statins) are drugs widely used in the treatment of hypercholesterolaemia. A large number of clinical trials (4S, CARE, WOSCOPS) has demonstrated that treatment of patients with statins reduces the number of cardiac or cerebral ischaemic events even in the absence of further reduction in serum cholesterol levels. In my opinion, these drugs (statins), since a long time, need to be supported with a large number of “ad hoc hypotheses”, not to speak of their presently well-known dangerous side-effects, I pointed out a lot of years ago. Infact, in 1990 I published already two papers (2, 3) (one of them in The Practitioner, Italian Edition), in which described the risk of CoQ10 lowering, brought about, as side-effect, by every statine utilized in those years. One year thereafter, I fully illustrated the same results of my clinical research by means of Biophysical Semeiotics in an italian Congress (2).
After 10 years all mass-media all over the world tell about rabdomyolysis and death caused by cerivastatin if prescribed in association with other anticholesteolemic drugs (fibrates). A part from the real role played by Cerivastatin, if prescribed without any hypocholesterolemic drugs, which will be in any way ascertained in next future, a fact must be underlined: the above-referred data of my research have been unfortunately overrlooked.
As a matter of fact, in the above-mentioned article I described, for the first time, the method to recognize “clinicaly”, i. e. at the bed-side, by means of a new, original physical semeiotics, the Biophysical Semeiotics, Co Q10 deficiency syndrome, even initial and asymptomatic.
Moreover, as far as this clinical method is concerned, it was been published and fully discussed elsewhere abundantly (4, 5, 6, 7). Notoriously, Co Q10 is an essential coenzyme, unavoidable in reaching the normal free energy level in every cell of the body, necessary for the physiology and biology of all biological systems, including scheletral muscle.
As regards “drugs” that can normalize endthelial cell functions, besides numerous other advantageous effects, I outline here Melatonin-Adenosine, according to the preparation of Di Bella –Ferrari, because I demonstrated recently its action as well as action mechanisms, untill now ignored (8, 9, 10).
In my opinion, it is very difficult to understand why General Practitioners, at the beginning of 2000, do not know the original semeiotics,i. e., Biophysical Semeiotics, cited in the best web-site, including bmj.com (See: http://digilander.iol.it/semeioticabiofisica), which allows doctor to evaluate “clinically” in quantitative manner, for instance, Co Q10 deficiency syndrome as well as Endothelial Cell Functions and “Oncological Terrain”, conditio sine qua non of malignancies occurrence (8).
1) Heinke S., Schwarz G., Figulla HR., Heinemann SH.The influence of statins on the free intracellular calcium concentration in human umbilical vein endothelial cells. BMC Cardiovascular Disorders 2004, 4:4 doi:10.1186/1471-2261-4-
http://www.biomedcentral.com/1471-2261/4/4/prepub
2) Stagnaro-Neri M., Stagnaro S., Carenza di Co Q10 secondaria a terapia ipolipidemizzante diagnosticata con la Percussione Ascoltata. Epat.(S.E.U.) 37, 17, 1990, and Settimana Italiana di Dietologia, 9-13 Aprile 1991, Merano. Atti, pg. 65.
3) Stagnaro S., Ipercolesterolemia e Coenzima Q10. The Pract. Ed. It. 133, 5-6, 1990).
4) Stagnaro-Neri M., Stagnaro S., Acidi grassi W-3, scavengers dei radicali liberi e attivatori del ciclo Q della sintesi del Co Q10. Gazz. Med. It. – Arch. Sc. Med. 151, 341, 1992.
5) Stagnaro-Neri M., Stagnaro S., Sindrome clinica percusso-ascoltatoria da carenza di Co Q10. Medic. Geriatr. XXIV, 239,1993.
6) Stagnaro-Neri M., Stagnaro S., Auscultatory Percussion Coenzyme Q deficiency Syndrome. VI Int. Symp., Biomedical and clinical aspects of Coenzyme Q. Rome, January 22.24, Chairmen K. Folkers, G.L. Littaru, T. Yamagani, Abs., pg. 105, 1990
7) Stagnaro-Neri M, Stagnaro S. C0Q10 in the prevention and treatment of primary osteoporosis. Preliminary data. Clin Ter. 1995 Mar;146(3):215-9 [Pub-Med indexed for MEDLINE]
8) Stagnaro Sergio, Stagnaro-Neri Marina. Introduzione alla Semeiotica Biofisica. Il Terreno oncologico”. Travel Factory SRL., Roma, 2004.
9) Stagnaro S., Stagnaro-Neri M., La Melatonina nella Terapia del Terreno Oncologico e del “Reale Rischio” Oncologico. Ediz. Travel Factory, Roma, 2004.
10) Stagnaro S., Stagnaro-Neri M., La Melatonina nella Terapia del Terreno Oncologico e del “Reale Rischio” Oncologico. Ediz. Travel Factory, Roma, 2004.
11) Stagnaro S., Stagnaro-Neri M., Le Costituzioni Semeiotico-Biofisiche.Strumento clinico fondamentale per la prevenzione primaria e la definizione della Single Patient Based Medicine. Ediz. Travel Factory, Roma, 2004.
Endothelial cell function can ameliorate under safer drugs, such as Melatonin-Adenosine.
10 October 2004
Sirs,
the authors conclude their intriguing paper stating that “The increase of resting [Ca2+]i after incubation with cerivastatin or fluvastatin may provide an explanation for the direct effects of statins on the endothelial-dependent vasodilatation and restoration of endothelial activity in vivo”. In addition, it is remembered that inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase (statins) are drugs widely used in the treatment of hypercholesterolaemia. A large number of clinical trials (4S, CARE, WOSCOPS) has demonstrated that treatment of patients with statins reduces the number of cardiac or cerebral ischaemic events even in the absence of further reduction in serum cholesterol levels. In my opinion, these drugs (statins), since a long time, need to be supported with a large number of “ad hoc hypotheses”, not to speak of their presently well-known dangerous side-effects, I pointed out a lot of years ago. Infact, in 1990 I published already two papers (2, 3) (one of them in The Practitioner, Italian Edition), in which described the risk of CoQ10 lowering, brought about, as side-effect, by every statine utilized in those years. One year thereafter, I fully illustrated the same results of my clinical research by means of Biophysical Semeiotics in an italian Congress (2).
After 10 years all mass-media all over the world tell about rabdomyolysis and death caused by cerivastatin if prescribed in association with other anticholesteolemic drugs (fibrates). A part from the real role played by Cerivastatin, if prescribed without any hypocholesterolemic drugs, which will be in any way ascertained in next future, a fact must be underlined: the above-referred data of my research have been unfortunately overrlooked.
As a matter of fact, in the above-mentioned article I described, for the first time, the method to recognize “clinicaly”, i. e. at the bed-side, by means of a new, original physical semeiotics, the Biophysical Semeiotics, Co Q10 deficiency syndrome, even initial and asymptomatic.
Moreover, as far as this clinical method is concerned, it was been published and fully discussed elsewhere abundantly (4, 5, 6, 7). Notoriously, Co Q10 is an essential coenzyme, unavoidable in reaching the normal free energy level in every cell of the body, necessary for the physiology and biology of all biological systems, including scheletral muscle.
As regards “drugs” that can normalize endthelial cell functions, besides numerous other advantageous effects, I outline here Melatonin-Adenosine, according to the preparation of Di Bella –Ferrari, because I demonstrated recently its action as well as action mechanisms, untill now ignored (8, 9, 10).
In my opinion, it is very difficult to understand why General Practitioners, at the beginning of 2000, do not know the original semeiotics,i. e., Biophysical Semeiotics, cited in the best web-site, including bmj.com (See: http://digilander.iol.it/semeioticabiofisica), which allows doctor to evaluate “clinically” in quantitative manner, for instance, Co Q10 deficiency syndrome as well as Endothelial Cell Functions and “Oncological Terrain”, conditio sine qua non of malignancies occurrence (8).
1) Heinke S., Schwarz G., Figulla HR., Heinemann SH.The influence of statins on the free intracellular calcium concentration in human umbilical vein endothelial cells. BMC Cardiovascular Disorders 2004, 4:4 doi:10.1186/1471-2261-4-
http://www.biomedcentral.com/1471-2261/4/4/prepub
2) Stagnaro-Neri M., Stagnaro S., Carenza di Co Q10 secondaria a terapia ipolipidemizzante diagnosticata con la Percussione Ascoltata. Epat.(S.E.U.) 37, 17, 1990, and Settimana Italiana di Dietologia, 9-13 Aprile 1991, Merano. Atti, pg. 65.
3) Stagnaro S., Ipercolesterolemia e Coenzima Q10. The Pract. Ed. It. 133, 5-6, 1990).
4) Stagnaro-Neri M., Stagnaro S., Acidi grassi W-3, scavengers dei radicali liberi e attivatori del ciclo Q della sintesi del Co Q10. Gazz. Med. It. – Arch. Sc. Med. 151, 341, 1992.
5) Stagnaro-Neri M., Stagnaro S., Sindrome clinica percusso-ascoltatoria da carenza di Co Q10. Medic. Geriatr. XXIV, 239,1993.
6) Stagnaro-Neri M., Stagnaro S., Auscultatory Percussion Coenzyme Q deficiency Syndrome. VI Int. Symp., Biomedical and clinical aspects of Coenzyme Q. Rome, January 22.24, Chairmen K. Folkers, G.L. Littaru, T. Yamagani, Abs., pg. 105, 1990
7) Stagnaro-Neri M, Stagnaro S. C0Q10 in the prevention and treatment of primary osteoporosis. Preliminary data. Clin Ter. 1995 Mar;146(3):215-9 [Pub-Med indexed for MEDLINE]
8) Stagnaro Sergio, Stagnaro-Neri Marina. Introduzione alla Semeiotica Biofisica. Il Terreno oncologico”. Travel Factory SRL., Roma, 2004.
http://www.travelfactory.it/semeiotica_biofisica.htm
9) Stagnaro S., Stagnaro-Neri M., La Melatonina nella Terapia del Terreno Oncologico e del “Reale Rischio” Oncologico. Ediz. Travel Factory, Roma, 2004.
10) Stagnaro S., Stagnaro-Neri M., La Melatonina nella Terapia del Terreno Oncologico e del “Reale Rischio” Oncologico. Ediz. Travel Factory, Roma, 2004.
11) Stagnaro S., Stagnaro-Neri M., Le Costituzioni Semeiotico-Biofisiche.Strumento clinico fondamentale per la prevenzione primaria e la definizione della Single Patient Based Medicine. Ediz. Travel Factory, Roma, 2004.
Competing interests
Not declared